New Study Suggests Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy Need More Dialogue with Health Care Provider, Especially Around Cardiovascular Risk

Overview

Journal World J Urol

Specialty Urology

Date 2018 Sep 24

PMID 30244335

Citations 2

Authors

Axel Merseburger

Anne Bro Falkenberg

Olga J Kornilova

Affiliations

Soon will be listed here.

Abstract

Purpose: To study the current level of patients' awareness, and patient-health care provider (HCP) dialogue with respect to treatment-related risks, especially cardiovascular risk (CVR) associated with advanced prostate cancer (PCa) treatment.

Methods: This 10-min online survey summarised data by treatment, region, and CVR (high or low).

Results: Of the 411 patients, 83% were at high CVR while only 8% patients were aware of CVR associated with PCa treatment, majority of which (80%) were informed about this risk by HCPs. No significant difference in treatment approach was reported, regardless of patient's CVR status. Compared to other potential risks, patients were more likely to initiate discussion about heart problems with HCPs (38% patients). When prompted, 26% patients rated heart problems as the most concerning risk factor, and this concern was twice in patients with high CVR (28%) versus low CVR (14%). Lifestyle modifications were made by 64% patients, of which 45% patients reported an improvement in overall well-being. Improved diet was the most adopted lifestyle modification.

Conclusion: There is a need to enhance a constant patient-HCP dialogue, and both groups need to make a conscious effort in that direction. This would help in increasing patients' awareness of risks, having better treatment choice and acceptance, and reducing side-effects.

Citing Articles

Prevalence and temporal trends of prostate diseases among inpatients with cardiovascular disease: a nationwide real-world database survey in Japan.

Kaneta K, Tanaka A, Nakai M, Sumita Y, Kaneko H, Noguchi M Front Cardiovasc Med. 2023; 10:1236144.

PMID: 37928758 PMC: 10620699. DOI: 10.3389/fcvm.2023.1236144.

[Factors influencing the choice of androgen deprivation therapy for patients with hormone-sensitive prostate cancer : Results of the ProComD study].

Lehmann J, Kluike C, Haider A, Haider K, Baumann S, Flesch M Urologe A. 2021; 61(2):173-182.

PMID: 34402941 PMC: 8831365. DOI: 10.1007/s00120-021-01620-7.

References

Keating N, OMalley A, Freedland S, Smith M . Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer?. Eur Urol. 2012; 64(1):159-66. PMC: 3683550. DOI: 10.1016/j.eururo.2012.04.035. View

Haque R, UlcickasYood M, Xu X, Cassidy-Bushrow A, Tsai H, Keating N . Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study. Br J Cancer. 2017; 117(8):1233-1240. PMC: 5674100. DOI: 10.1038/bjc.2017.280. View

Nguyen P, Chen M, Hoffman K, Chen R, Hu J, Bennett C . Cardiovascular comorbidity and treatment regret in men with recurrent prostate cancer. BJU Int. 2011; 110(2):201-5. DOI: 10.1111/j.1464-410X.2011.10709.x. View

Latorzeff I, Ploussard G, Guillotreau J, Jonca F, Labarthe P, Rollin G . [Cardiovascular risks with prostate cancer hormonal treatment: rationale for a department of oncocardiology]. Cancer Radiother. 2016; 20(5):405-10. DOI: 10.1016/j.canrad.2016.02.015. View

Van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt O, Bill-Axelson A . Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. J Clin Oncol. 2010; 28(21):3448-56. DOI: 10.1200/JCO.2010.29.1567. View

Tsai H, DAmico A, Sadetsky N, Chen M, Carroll P . Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007; 99(20):1516-24. DOI: 10.1093/jnci/djm168. View

Davis M, Rajala J, Tyldesley S, Pickles T, Virani S . The Prevalence of Cardiac Risk Factors in Men with Localized Prostate Cancer Undergoing Androgen Deprivation Therapy in British Columbia, Canada. J Oncol. 2015; 2015:820403. PMC: 4537764. DOI: 10.1155/2015/820403. View

Fourcade R, Mensink P, Ernemo B, Ligensa C . The value of patient-doctor dialog in the treatment of early prostate cancer. Prostate Cancer Prostatic Dis. 2002; 5 Suppl 2:S12-4. DOI: 10.1038/sj.pcan.4500623. View

Tao Z, Shi A, Wang K, Zhang W . Epidemiology of prostate cancer: current status. Eur Rev Med Pharmacol Sci. 2015; 19(5):805-12. View

10.

Gandaglia G, Sun M, Popa I, Schiffmann J, Trudeau V, Shariat S . Cardiovascular mortality in patients with metastatic prostate cancer exposed to androgen deprivation therapy: a population-based study. Clin Genitourin Cancer. 2014; 13(3):e123-30. DOI: 10.1016/j.clgc.2014.12.003. View

11.

Greiman A, Keane T . Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease. Curr Urol Rep. 2017; 18(6):41. DOI: 10.1007/s11934-017-0688-5. View

12.

Schostak M, Wiegel T, Muller M, Hoecht S, Schrader M, Straub B . Shared decision-making--results from an interdisciplinary consulting service for prostate cancer. World J Urol. 2004; 22(6):441-8. DOI: 10.1007/s00345-004-0447-3. View

13.

Crawford E, Moul J . ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injury. Oncology (Williston Park). 2015; 29(1):55-8, 65-6. View

14.

Sommers B, Beard C, DAmico A, Kaplan I, Richie J, Zeckhauser R . Predictors of patient preferences and treatment choices for localized prostate cancer. Cancer. 2008; 113(8):2058-67. DOI: 10.1002/cncr.23807. View

15.

Hardy C, Penn S, Morris T . Attitudes of prostate cancer patients towards the diagnosis and treatment of their disease: findings from a multinational survey. Curr Med Res Opin. 2007; 23(9):2107-16. DOI: 10.1185/030079907X223800. View

16.

Keating N, OMalley A, Freedland S, Smith M . Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2009; 102(1):39-46. PMC: 3107568. DOI: 10.1093/jnci/djp404. View

17.

Fu A, Tsai H, Haque R, Yood M, Cassidy-Bushrow A, Van Den Eeden S . Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer. J Urol. 2016; 197(6):1448-1454. PMC: 5433922. DOI: 10.1016/j.juro.2016.12.086. View

18.

Bhatia N, Santos M, Jones L, Beckman J, Penson D, Morgans A . Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer: ABCDE Steps to Reduce Cardiovascular Disease in Patients With Prostate Cancer. Circulation. 2016; 133(5):537-41. PMC: 5029929. DOI: 10.1161/CIRCULATIONAHA.115.012519. View

19.

Watson E, Shinkins B, Frith E, Neal D, Hamdy F, Walter F . Symptoms, unmet needs, psychological well-being and health status in survivors of prostate cancer: implications for redesigning follow-up. BJU Int. 2015; 117(6B):E10-9. DOI: 10.1111/bju.13122. View

20.

Snow S, Panton R, Butler L, Wilke D, Rutledge R, Bell D . Incomplete and inconsistent information provided to men making decisions for treatment of early-stage prostate cancer. Urology. 2007; 69(5):941-5. DOI: 10.1016/j.urology.2007.01.027. View